Back
Arbutus Biopharma Quote, Financials, Valuation and Earnings
Sponsored
ABUS
Sponsored
Trump's IRS Hands Massive 'Victory Gift' To 401K Owners
Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.
Sell
40
ABUS
Arbutus Biopharma
Last Price:
3.66
Seasonality Move:
13.65%
7 Day Trial
ALL ACCESS PASS
$
7
U.S. Government Report Alert Tuesday
Discover the Secret LoopholeArbutus Biopharma Price Quote
$3.66
+0.01 (+0.27%)
(Updated: November 13, 2024 at 5:55 PM ET)
Arbutus Biopharma Key Stats
Sell
40
Arbutus Biopharma (ABUS)
is a Sell
Day range:
$3.61 - $3.75
52-week range:
$1.75 - $4.73
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
97.62
P/B ratio:
6.47%
Volume:
777.7K
Avg. volume:
827.9K
1-year change:
106.21%
Market cap:
$691.6M
Revenue:
$18.1M
EPS:
$-0.43
How Much Does Arbutus Biopharma Make?
-
How Much Are Arbutus Biopharma's Sales Annually?
ABUS Revenues are $18.1M -
How Much Profit Does Arbutus Biopharma's Make A Year?
ABUS net income is -$72.8M
Is Arbutus Biopharma Growing As A Company?
-
What Is Arbutus Biopharma's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.71% -
What Is Arbutus Biopharma's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Arbutus Biopharma Stock Price Performance
-
Did Arbutus Biopharma Stock Go Up Last Month?
Arbutus Biopharma share price went down by -5.93% last month -
Did ABUS's Share Price Rise Over The Last Year?
ABUS share price rose by 106.21% over the past 1 year
What Is Arbutus Biopharma 52-Week High & Low?
-
What Is Arbutus Biopharma’s 52-Week High Share Price?
Arbutus Biopharma has traded as high as $4.73 over the past 52 weeks -
What Is Arbutus Biopharma’s 52-Week Low Share Price?
Arbutus Biopharma has traded as low as $1.75 over the past 52 weeks
Arbutus Biopharma Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Arbutus Biopharma?
-
How Much Debt Does Arbutus Biopharma Have?
Total long term debt quarterly is $0 -
How Much Cash Does Arbutus Biopharma Have?
Cash and short term investments quarterly total is $127.8M -
What Is Arbutus Biopharma’s Book Value Per Share?
Book value per share is 0.56
Is Arbutus Biopharma Cash Flow Positive?
-
What Is ABUS Cash Flow From Operations?
Cash flow from operations (TTM) is -$71.8M -
What Is Arbutus Biopharma’s Cash Flow From Financing?
Cash flow from financing (TTM) is $54.4M -
What Is Arbutus Biopharma’s Cash Flow From Investing?
Cash flow from investing (TTM) is $31.8M
Arbutus Biopharma Return On Invested Capital
-
Is Management Doing A Good Job?
ABUS return on invested capital is -67.36% -
What Is Arbutus Biopharma Return On Assets?
ROA measures how assets are converting to revenues and is -50.88% -
What Is ABUS Return On Equity?
ROE is a measure of profitability and is -67.36%
Arbutus Biopharma Earnings Date & Stock Price
-
What Is Arbutus Biopharma's Stock Price Today?
A single share of ABUS can be purchased today for 3.65 -
What Is Arbutus Biopharma’s Stock Symbol?
Arbutus Biopharma trades on the nasdaq under the ticker symbol: ABUS -
When Is Arbutus Biopharma’s Next Earnings Date?
The next quarterly earnings date for Arbutus Biopharma is scheduled on February 28, 2025 -
When Is ABUS's next ex-dividend date?
Arbutus Biopharma's next ex-dividend date is May 26, 2020 -
How To Buy Arbutus Biopharma Stock?
You can buy Arbutus Biopharma shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Arbutus Biopharma Competitors
-
Who Are Arbutus Biopharma's Competitors?
Below is a list of companies who compete with Arbutus Biopharma or are related in some way:
Arbutus Biopharma Dividend Yield
-
What Is ABUS Dividend Yield?
Arbutus Biopharma’s dividend yield currently is 0% -
What Is Arbutus Biopharma’s Payout Ratio?
Arbutus Biopharma’s payout ratio is 0% -
When Did Arbutus Biopharma Last Pay A Dividend?
The latest dividend pay date is November 14, 2024 -
What Is Arbutus Biopharma’s Dividend Per Share?
Arbutus Biopharma pays a dividend of $0.00 per share
Arbutus Biopharma Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | -5.95% |
Revenue: | -71.25% | -28.55% |
Analyst Recommendations
Buy Recommendations: | 2 |
---|---|
Hold Recommendations: | 1 |
Sell Recommendations: | 0 |
Price Target: | 5.09 |
Upside from Last Price: | 39.47% |